AMAG Pharmaceuticals (AMAG) Announces FDA Approval of Feraheme
Down)
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said the FDA has granted marketing approval for Feraheme Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later. Feraheme should be administered as an undiluted IV injection delivered at a rate of up to 1 mL/sec (30 mg/sec). The recommended Feraheme dose may be readministered to patients with persistent or recurrent iron deficiency anemia.
The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later. Feraheme should be administered as an undiluted IV injection delivered at a rate of up to 1 mL/sec (30 mg/sec). The recommended Feraheme dose may be readministered to patients with persistent or recurrent iron deficiency anemia.
You May Also Be Interested In
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
